Mitesco (MITI) 10-K 17 Apr 18 2017 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2017	Apr. 02, 2018	Jun. 30, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	True Nature Holding, Inc.
Document Type	10-K
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		20,835,997
Entity Public Float			$ 3,816,758
Amendment Flag	false
Entity Central Index Key	802,257
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Current assets
Cash and cash equivalents	$ 0	$ 0
Prepaid expenses and other current assets	0	1,875
Total current assets	0	1,875
Total Assets	0	1,875
Current liabilities
Accounts payable	766,356	589,229
Accrued liabilities – related party	147,894	84,488
Due to related parties	91,066	106,866
Accrued interest	50,665	31,021
Convertible note payable	60,000	0
Convertible note payable, in default	196,270	256,270
Note payable - related party	75,000	0
Total current liabilities	1,387,251	1,067,874
Commitments and contingencies
Stockholders’ equity (deficit)
Preferred stock, $0.01 par value, 10,000,000 shares authorized, no shares issued or outstanding as of December 31, 2017 and 2016	0	0
Common stock, $0.01 par value, 500,000,000 shares authorized, 18,930,874 and 17,436,666 shares issued and outstanding as of December 31, 2017 and 2016	189,309	174,367
Additional paid-in capital	4,659,713	4,261,748
Stock payable	39,886	20,000
Accumulated deficit	(6,276,159)	(5,522,114)
Total (deficiency in) stockholders’ equity	(1,387,251)	(1,065,999)
Total liabilities and stockholders’ equity	$ 0	$ 1,875

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2017	Dec. 31, 2016
Preferred stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	18,930,874	17,436,666
Common stock, shares outstanding	18,930,874	17,436,666

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Revenue	$ 0	$ 0
Operating expenses:
General and administrative	699,957	4,405,163
Total operating expenses	699,957	4,405,163
Net Operating Loss	(699,957)	(4,405,163)
Other income (expense):
Interest expense	(54,088)	(269,367)
Loss on debt extinguishment	0	(206,329)
Total other expense	(54,088)	(475,696)
Loss before provision for income taxes	(754,045)	(4,880,859)
Provision for income taxes	0	0
Net loss	$ (754,045)	$ (4,880,859)
Net loss per share - basic (in Dollars per share)	$ (0.04)	$ (0.35)
Net loss per share - diluted (in Dollars per share)	$ (0.04)	$ (0.35)
Weighted average shares outstanding - basic (in Shares)	17,766,522	13,760,888
Weighted average shares outstanding - diluted (in Shares)	17,766,522	13,760,888

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders’ Deficit - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Stock Payable [Member]	Retained Earnings [Member]	Total
Balance, Value at Dec. 31, 2015	$ 117,650	$ 3,917		$ (641,255)	$ (519,688)
Balance Share (in Shares) at Dec. 31, 2015	11,765,000
Stock issued for cash	$ 1,100	49,800			$ 51,000
Stock issued for cash (in Shares)	120,000				120,000
Stock issued for services					$ 3,377,735
Stock issued for services (in Shares)					4,070,000
Beneficial conversion features		67,062			$ 67,062
Stock based compensation	$ 40,700	3,337,035	$ 0		3,377,735
Stock based compensation (in Shares)	4,070,000
Common stock and warrants issued and payable for debt discount	$ 150	118,601	20,000		138,751
Common stock and warrants issued and payable for debt discount (in Shares)	15,000
Common stock issued for conversion of accounts payable or accrued interest	$ 10,667	569,333			580,000
Common stock issued for conversion of accounts payable or accrued interest (in Shares)	1,066,666
Net loss				(4,880,859)	(4,880,859)
Balance, Value at Dec. 31, 2016	$ 174,367	4,261,748	20,000	(5,522,114)	$ (1,065,999)
Balance Share (in Shares) at Dec. 31, 2016	17,436,666				17,436,666
Stock issued for cash	$ 2,500	44,500			$ 47,000
Stock issued for cash (in Shares)	250,000				50,000
Stock issued for services	$ 21,136	222,462	17,936	0	$ 261,534
Stock issued for services (in Shares)	2,113,637
Stock issued for extension of debt	$ 650	8,173	1,950	0	10,773
Stock issued for extension of debt (in Shares)	65,000
Beneficial conversion features					0
Common stock and warrants issued and payable for debt discount					10,773
Common stock issued for conversion of accounts payable or accrued interest	$ 12,156	96,830			$ 108,986
Common stock issued for conversion of accounts payable or accrued interest (in Shares)	1,215,571				65,000
Imputed interest		4,500			$ 4,500
Stock returned for cancellation by prior officer	$ (21,500)	21,500			0
Stock returned for cancellation by prior officer (in Shares)	(2,150,000)
Net loss			0	(754,045)	(754,045)
Balance, Value at Dec. 31, 2017	$ 189,309	$ 4,659,713	$ 39,886	$ (6,276,159)	$ (1,387,251)
Balance Share (in Shares) at Dec. 31, 2017	18,930,874				18,930,874

Consolidated Statement of Cash

Consolidated Statement of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (754,045)	$ (4,880,859)
Adjustments to reconcile net loss to net cash used in operating activities:
Gain on conversion of accrued interest	4,500	0
Loss on extinguishment of debt	0	206,329
Debt discount amortization	0	249,592
Shares issued for extension of note payable	10,773	0
Stock based compensation	261,534	3,377,736
Changes in assets and liabilities:
Prepaid expenses	1,875	15,125
Accounts payable	286,113	564,766
Accrued liabilities	63,406	74,028
Due to related parties	59,200	106,866
Accrued interest	19,644	16,909
Net cash used in operating activities	(47,000)	(269,508)
CASH FLOWS FROM INVESTING ACTIVITIES
Net cash provided by investing activities	0	0
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of convertible note payable	0	258,000
Sale of common stock, net of issuance costs	47,000	51,000
Repayment of promissory notes	0	(67,677)
Net cash provided by financing activities	47,000	241,323
Net increase (decrease) in cash and cash equivalents	0	(28,185)
Cash and cash equivalents at beginning of period	0	28,185
Cash and cash equivalents at end of period	0	0
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Interest paid	0	0
Income taxes paid	0	0
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Beneficial Conversion Feature	0	67,062
Conversion of debt to common stock	0	103,671
Discount related to issuance of debentures, warrants and convertible notes	0	138,750
Par value of shares returned for cancellation	21,500	0
Note payable issued to related party for accounts payable to related party	75,000	0
Accounts Payable [Member]
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Conversion of debt to common stock	$ 108,986	$ 390,000

Note 1 - Organization, Basis of

Note 1 - Organization, Basis of Presentation and Nature of Operations	12 Months Ended
	Dec. 31, 2017
Disclosure Text Block [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1 – Organization, Basis of Presentation and Nature of Operations True Nature Holding, Inc. (the “Company”), previously known as Trunity Holdings, Inc., became a publicly-traded company through a reverse merger with Brain Tree International, Inc., a Utah corporation (“BTI”). BTI was incorporated on July 26, 1983 to specialize in the development of high technology products or applications including, but not limited to, electronics, computerized technology, new technological product fields, and precious metals. Trunity Holdings, Inc. was the parent company of the prior educational business, named Trunity, Inc., which was formed on July 28, 2009 through the acquisition of certain intellectual property by its three founders. True Nature Holding, Inc. is a corporation organized under the laws of the state of Delaware with principal offices located in Atlanta, Georgia. On January 16, 2016, the Company changed the equity structure that included a reverse split of 1 for 101, such that all holders of 101 shares of common stock issued and outstanding prior to the effective date of the reverse split would own 1 share of common stock upon the effect date of the reverse split. In addition, the Company amended its Articles of Incorporation (i) to increase its authorized capital stock to 510,000,000 shares which consists of 500,000,000 shares of common stock, par value $0.01 per share, and 10,000,000 shares of preferred stock, par value $0.01 per share and (ii) to change its name from Trunity Holdings, Inc. to True Nature Holding, Inc. (there was no change in the stock symbol “TNTY”). The accompanying consolidated financial statements include the accounts of True Nature Holding, Inc. as December 31, 2017 and 2016.

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	Note 2 – Summary of Significant Accounting Policies Basis of Accounting Use of Estimates - Comprehensive Loss – Cash - Revenue Recognition – Stock-Based Compensation – Equity instruments issued to other than employees are recorded on the basis of the fair value of the instruments. In general, the measurement date is when either a (a) performance commitment, as defined, is reached or (b) the earlier of (i) the non-employee performance is complete or (ii) the instruments are vested. The measured value related to the instruments is recognized over a period based on the facts and circumstances of each particular grant. Convertible Instruments Common Stock Purchase Warrants – Stockholders’ Equity – Per Share Data – The Company has excluded all common equivalent shares outstanding for warrants, options and convertible instruments to purchase common stock from the calculation of diluted net loss per share because all such securities are antidilutive for the periods presented. As of December 31, 2017 and 2016, the Company had no outstanding warrants or options. Income Taxes – Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company has determined that a valuation allowance is needed due to recent taxable net operating losses, the sale of profitable divisions and the limited taxable income in the carry back periods. The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income or expense in the period that includes the enactment date. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and certain tax loss carryforwards, less any valuation allowance. The Company accounts for uncertain tax positions as required in that a position taken or expected to be taken in a tax return is recognized in the consolidated financial statements when it is more likely than not (i.e., a likelihood of more than fifty percent) that the position would be sustained upon examination by tax authorities. A recognized tax position is then measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. The Company does not have any material unrecognized tax benefits. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as components of interest expense and other expense, respectively, in arriving at pretax income or loss. The Company does not have any interest and penalties accrued. The Company is generally no longer subject to U.S. federal, state, and local income tax examinations for the years before 2012. Business Combinations – ● future expected cash flows from product sales, support agreements, consulting contracts, other customer contracts, and acquired developed technologies and patents; and ● discount rates utilized in valuation estimates. Unanticipated events and circumstances may occur that may affect the accuracy or validity of such assumptions, estimates or actual results. Additionally, any change in the fair value of the acquisition-related contingent consideration subsequent to the acquisition date, including changes from events after the acquisition date, such as changes in our estimates of relevant revenue or other targets, will be recognized in earnings in the period of the estimated fair value change. A change in fair value of the acquisition-related contingent consideration or the occurrence of events that cause results to differ from our estimates or assumptions could have a material effect on the consolidated financial position, statements of operations or cash flows in the period of the change in the estimate. Impairment of Long – Lived Assets- Financial Instruments and Fair Values – Level 1 – inputs include exchange quoted prices for identical instruments and are the most observable. Level 2 – inputs include brokered and/or quoted prices for similar assets and observable inputs such as interest rates. Level 3 – inputs include data not observable in the market and reflect management judgment about the assumptions market participants would use in pricing the asset or liability. The use of observable and unobservable inputs and their significant in measuring fair value are reflected in our hierarchy assessment. The carrying amount of cash, prepaid assets, accounts payable and accrued liabilities approximates fair value due to the short-term maturities of these instruments. Because cash and cash equivalents are readily liquidated, management classifies these values as Level 1. The fair value of the debentures, approximate their book value as the instruments are short-term in nature and contain market rates of interest. Because there is no ready market or observable transactions, management classifies the debentures as Level 3. Recently Issued Accounting Standards In May 2017, the FASB issued ASU No. 2017-09, Stock Compensation - Scope of Modification Accounting, which provides guidance on which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. The ASU requires that an entity should account for the effects of a modification unless the fair value (or calculated value or intrinsic value, if used), vesting conditions and classification (as equity or liability) of the modified award are all the same as for the original award immediately before the modification. The ASU becomes effective for the Company on January 1, 2018, and should be applied prospectively to an award modified on or after the adoption date. Early adoption is permitted, including adoption in any interim period. The Company will apply this standard for any awards that are modified after January 1, 2018. We are evaluating what impact, if any, the adoption of this guidance will have on our financial condition, results of operations, cash flows or financial disclosures. In January 2017, the FASB issued ASU No. 2017-04, Simplifying the Test for Goodwill Impairment, which simplifies the subsequent measurement of goodwill by eliminating Step 2 from the goodwill impairment test. In computing the implied fair value of goodwill under Step 2, current U.S. GAAP requires the performance of procedures to determine the fair value at the impairment testing date of assets and liabilities (including unrecognized assets and liabilities) following the procedure that would be required in determining the fair value of assets acquired and liabilities assumed in a business combination. Instead, the amendments under this ASU require the goodwill impairment test to be performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. The ASU becomes effective for the Company on January 1, 2020. The amendments in this ASU should be applied on a prospective basis. Early adoption is permitted for interim or annual goodwill impairment tests performed. We are evaluating what impact, if any, the adoption of this guidance will have on our financial condition, results of operations, cash flows or financial disclosures. In August 2016, the FASB issued ASU No. 2016-15 which amends ASC Topic 230, “Classification of Certain Cash Receipts and Cash Payments.” The amendments in this update address eight specific cash flow issues with the objective of reducing the existing diversity in practice. The update outlines the classification of specific transactions as either cash inflows or outflows from financing activities, operating activities, investing activities or non-cash activities. This guidance is effective for interim and annual reporting periods beginning after December 15, 2017. We are evaluating what impact, if any, the adoption of this guidance will have on our financial condition, results of operations, cash flows or financial disclosures. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), to increase transparency and comparability among organizations by recognizing a right-of-use asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either operating or financing, with such classification affecting the pattern of expense recognition in the income statement. ASU 2016-02 is effective for fiscal years and interim periods within those years beginning after December 15, 2018, and early adoption is permitted. We are currently evaluating the impact ASU 2016-02 will have on our consolidated financial statements and associated disclosures. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), to clarify the principles of recognizing revenue and create common revenue recognition guidance between U.S. GAAP and International Financial Reporting Standards. Under ASU 2014-09, revenue is recognized when a customer obtains control of promised goods or services and is recognized at an amount that reflects the consideration expected to be received in exchange for such goods or services. In addition, ASU 2014-09 requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The ASU is effective for fiscal years beginning after December 15, 2017. The new revenue standard is principle based and interpretation of those principles may vary from company to company based on their unique circumstances. It is possible that interpretation, industry practice, and guidance may evolve as companies and the accounting profession work to implement this new standard. The Company is still in the process of evaluating the effect of the new standard on the Company’s historical financial statements and disclosures. While the Company has not completed its evaluation, the Company currently believes that the impact to revenue and expense recognized will not be material to any of the years presented. Management does not believe that any other recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on the accompanying condensed consolidated financial statements.

Note 3 - Deconsolidation of acq

Note 3 - Deconsolidation of acquisition	12 Months Ended
	Dec. 31, 2017
Deconsolidation of Acquisition [Abstract]
Deconsolidation of Acquisition [Text Block]	Note 3 –Deconsolidation of acquisition On April 29, 2016, subject to approval by the Georgia Board of Pharmacy, the Company entered into definitive documents to acquire P3 Compounding of Georgia, LLC, (“P3”). P3 received Georgia Board of Pharmacy approval for the transaction at the end of June 2016 and the transaction closed effective June 30, 2016. However after the following 90 days of operation, as the Company did not gain effective control, we entered into an agreement with the former owners to deconsolidate the operations and returned the assets and liabilities to the former owners of P3. The fair value of the consideration paid pertaining to the acquisition of P3 was $1,618,200. Consideration for the transaction was structured as follows: The Company issued 340,000 shares of common stock with a fair value of $1,183,200 based on the closing price of the True Nature’s common stock on April 29, 2016. In addition, Mr. Casey Gaetano, a former owner of P3, received an employment contract with True Nature for 3 years as VP of Corporate Development, at an annual salary of $125,000, plus normal benefits commensurate with other executives in the Company of equal stature. He also received on April 29, 2016, 125,000 shares of restricted at a value of $3.48 per share in exchange for becoming the Company’s VP of Corporate Development. No cash consideration was paid under this agreement, and it was fully cancelled without further obligation as a part of the deconsolidation transaction. The shares were valued at $435,000 and will remain the property of Mr. Gaetano. As the company never attained full control of P3, the business was deconsolidated from the company’s financials as of September 30, 2016. Loss on Deconsolidation As the Company did not obtain effective control of the P3 business, the Company deconsolidated the business effective September 30, 2016 in accordance with ASC 810 and the disclosures herein were also made in accordance with ASC 810. As a result, the Company recorded a loss from deconsolidation of $1,618,200, based on the fair value of shares issued of $1,618,200; the loss from deconsolidation is included within selling, general and administrative expenses.

Note 4 - Related Party Transact

Note 4 - Related Party Transactions	12 Months Ended
	Dec. 31, 2017
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	Note 4 – Related Party Transactions For the Year Ended December 31, 2016 On January 25, 2016 two board members were each awarded 100,000 of shares of the Company’s common stock in exchange for their services as board members. The shares were valued at $145,000 based on the closing market price on the date of grant. On April 25, 2016 a board member was awarded 100,000 shares of the Company’s common stock in exchange for his services on the board and non-qualified stock options to purchase up to 1,000,000 shares of the Company’s common stock in consideration for his services as CEO. The stock options were subsequently cancelled in conjunction with his resignation as CEO on September 23, 2016, and 100,000 shares of restricted common stock valued at $47,680, based on the closing market price on the date of grant, in conjunction with the cancellation of all amounts owed as of the date of his resignation. On May 25, 2016, a board member was awarded 100,000 shares of the Company’s common stock, valued at $235,000 based on the closing market price on the date of grant, in exchange for his service as a member of the board. On September 23, 2016, the Company appointed three new directors to the Board of Directors, and each received 100,000 shares of common stock, each valued at $27,990 based on the closing market price on the date of grant, in conjunction with their appointments. On September 27, 2016, the Company accepted the resignations of its former Chairman and CFO and former CEO. The former CFO had a consulting agreement in the amount of $10,000 per month for professional fees. The Company’s former CEO had an employment agreement effective June 7, 2016 pursuant to which he received a monthly salary in the amount of $12,500 per month for the remainder of the 2016 calendar year, $17,500 per month for the 2017 calendar year, $22,500 per month for the 2018 calendar year and $25,000 per month for the 2019 calendar year. No payments have been made to the former CEO. Both of these agreements were cancelled and the Company has no further obligation to either individuals going forward. Further, the former CFO has agreed to return for cancellation 2,000,000 shares of restricted common stock of the Company, and to use 100,000 shares of Company common stock to settle an obligation to a former employee. The former CEO had been awarded options for the purchase of 1,000,000 shares of restricted common stock, which were all cancelled in conjunction with his resignation. In addition, the Company had a consulting agreement with a shareholder in the amount of $10,000 per month for professional fees. The shareholder and the Company have agreed to terminate the agreement as of September 30, 2016. In consideration of all amounts owed, the Company issued 966,666 shares of common stock, valued at $290,000 based on the closing market price on the date of grant, and the consultant cancelled $290,000 in amounts owed. The amounts owed consist of a) $80,000 in advances to the Company, or obligations paid to the Company, b) $120,000 in consulting fees owed and c) reimbursement of $90,000 of costs related to the formation of Newco4pharmacy, LLC, which was acquired by the Company in December 2015. On December 30, 2016, the Board of Directors of the Company issued 100,000 shares of restricted common stock to a consultant, who subsequently became the CEO and CFO of the Company as compensation for his contribution during the prior 90 days. The charge to earnings for this issuance was $19,080. On December 30, 2016, the Board voted to issue 100,000 shares of common stock to each of the Company’s Board members as additional compensation for services during the prior 90 days. Each of the recipients abstained from the vote on their issuance so as not to be voting on their own issuance; however, each member of the Board voted for the issuance of shares to their fellow Board members. The charge to earnings for this issuance was $19,080, for each of the three directors, or a total of $57,240. The Company had accounts payable from related party transactions of $106,866 as of December 31, 2016. The balance was made up of the following: a) two members of the Board of Directors were due $12,000 each for compensation expense that had not been paid; b) the former CEO and CFO of the Company were owed for reimbursable expenses that totaled $75,866; and c) a shareholder paid for expenses of the Company directly to several vendors in the aggregate amount of $7,000. For the Year Ended December 31, 2017 During the year ended December 31, 2017, the Company raised gross proceeds of $47,000 through the sale of 250,000 shares of common stock to a new member of the Board of Directors at a price of $0.157 per share. During the year ended December 31, 2017, the Company issued 1,533,571 restricted shares of the Company’s common stock valued at $179,024 in exchange for services conducted on behalf of the Company by related parties. The Company also has accrued liabilities to related parties in the amount of $147,894 representing accrued compensation, $91,066 due to related parties for services provided and a note payable to a related party in the amount of $75,000. Interest expense in the amount of $4,500 was imputed on this note payable during the year ended December 31, 2017 (see note 5).

Note 5 - Debt

Note 5 - Debt	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	Note 5 – Debt On March 18, 2016, the Company issued a 12% Convertible Promissory Note (the “Convertible Note A”) in the principal amount of $60,000 to a lender. Upon issuance of the Convertible A Note, the lender was awarded 15,000 restricted common stock as an origination fee which includes piggy back registration rights. On September 19, 2016, the Company issued the lender an additional 15,000 restricted common stock at a price of $0.30 per share to extend the term of the loan agreement indefinitely. The cost to the Company was $4,050 in interest expense. On August 10, 2017, the Company issued 25,000 shares of common stock with a fair value of $3,750 for an additional extension of the term of the loan. Accrued interest at December 31, 2017 and December 31, 2016, was $10,860 and $3,660, respectively. Pursuant to the terms of the Convertible Note A, the Company is obligated to pay monthly installments of not less than $1,000 the first of each month commencing the month following the execution of the Convertible Note A until its maturity on September 16, 2016 at which time the Company is obligated to repay the full principal amount of the Convertible Note A. The Convertible Note A is convertible by the holder at any time into shares of the Company’s common stock at price of $1.00 per share, and throughout the duration of the note, the holder has the right to participate in any financing the Company may engage in upon the same terms and conditions as all other investors. The Company allocated the face value of the Convertible Note A to the shares and the note based on relative fair values, and the amount allocated to the shares of $18,750 was recorded as a discount against the note. The beneficial conversion feature of $9,375 was recorded as a debt discount with an offsetting entry to additional paid-in capital decreasing the note payable and increasing debt discount. The debt discount is being amortized to interest expense over the term of the debt. For the year ended December 31, 2016, debt discount amortization related to the Convertible Note A was $28,125. There was no amortization of the discount during the year ended December 31, 2017. On May 19, 2016, the Company issued a 10% Convertible Promissory Note (the “Convertible Note B”) in the principal amount of $100,000 to a lender. Upon issuance of the Convertible Note B, the lender was awarded 24-month warrants to purchase up to 66,666 shares of the Company’s common stock at an exercise price of $2.50 per share. The warrants were valued at $103,086 with $100,000 as a debt discount; the additional $3,086 was expensed as additional interest expense. The debt discount was fully amortized during the year ended December 31, 2016. This obligation, including all warrants, penalties and interest due was cancelled as of September 30, 2016 in consideration of the issuance of 400,000 shares of restricted common stock valued at $120,000. At the time of conversion, the principal amount of the note was approximately $100,000 and total accrued interest thereon was $3,671. As a result of the conversion, a loss of $16,329 recognized in the year ended December 31, 2016. August 2014 Convertible Debentures (Series C) As part of the restructuring all debentures issued by Trunity Holdings, Inc., to fund the former, educational business were eligible to participate in a debt conversion; however, one debenture holder that was issued a Series C Convertible Debenture (the “Series C Debenture”) in August 2014 with an aggregate face value of $100,000 in exchange for the cancellation of Series B Convertible Debentures with a carrying value of $110,833 did not convert such debenture. The Series C Debenture accrues interest at an annual rate of 10%, matured November 2015, and is convertible into our common stock at a conversion rate of $20.20 per share. The holders of the Series C Debenture also received five year warrants to acquire up to 4,950 shares post-split of common stock for an exercise price of $20.20 per share,. The former educational business allocated the face value of the Series C Debenture to the warrants and the debentures based on its relative fair values, and allocated to the warrants, which was recorded as a discount against the Series C Debenture, with an offsetting entry to additional paid-in capital. The discount was fully expensed upon execution of the new debentures as debt extinguishment costs within discontinued operations. As of December 31, 2017 and 2016, the carrying value of this Series C Debenture was $110,833 and accrued interest expense of $35,504 and $24,420, respectively. The Series C Debenture is currently in default. November 2014 Convertible Debentures (Series D) As part of the restructuring all debentures issued by Trunity Holdings, Inc., to fund the former, educational business were eligible to participate in a debt conversion; however, one debenture holder that was issued a Series D Convertible Debenture (the “Series D Debenture”) in November 2014 with an aggregate face value of $10,000 in exchange for the cancellation of Series B Convertible Debenture with a carrying value of $11,333 did not participate in the debt conversion restructuring. The Series D Debenture accrues interest at an annual rate of 12%, matured November 2015, and is convertible into our common stock at a conversion rate of $16.67 per share. The holders of the Series D Debenture also received five year warrants to acquire up to 495 shares of common stock for an exercise price of $20.20 per share on a post-split basis. The former educational business allocated the face value of the Series D Debenture to the warrants and the debentures based on their relative fair values, and allocated to the warrants, which was recorded as a discount against the Series D Debenture, with an offsetting entry to additional paid-in capital. The discount was fully expensed upon execution of the new debentures as debt extinguishment costs within discontinued operations. As of December 31, 2017 and 2016, the carrying value of the Series D Debenture was $11,333 and accrued interest expense of $4,301 and $2,941, respectively. The Series D Debenture is currently in default. March 2016 Convertible Note On March 18, 2016, the Company issued a 12% Convertible Promissory Note (the “Convertible Note A”) in the principal amount of $60,000 and a due date of September 16, 2016 to a lender. Short term loan As a result of the acquisition of P3 Compounding of Georgia, LLC (“P3”) the Company had a short-term convertible note with a loan agency in the principal amount of $52,000 for the purchase of future sales and credit card receivables of P3. Under the terms of the receivable purchase agreement, the Company purchased an advance of $50,000 plus $2,000 for origination costs with a 10.5% daily interest rate to be repaid over 160 days at a repayment amount of $451.75 per day. Upon maturity, the total repayment amount will be $72,280. As of December 31, 2017 and 2016 the carrying value of this short-term loan was $74,104 and 26,925, respectively. For year ending December 31, 2016, no interest expense related to this loan was recorded in the Company’s consolidated financial statements as the effective date of acquisition was the last day of the quarter. The origination fee and interest were recorded as debt discount on the date of issuance in the amount of $22,280 was amortized during the year ending December 31, 2016. No interest expense was charged on this loan during the twelve months ended December 31, 2017. During the years ended December 31, 2017 and 2016, principal payments in the amount of $67,676 and $0, respectively, were made on this loan. This loan is currently in default. July 2017 Note On July 10, 2017, the Company negotiated the reclassification of $75,000 in accounts payable to a related party to a loan payable (the “July 2017 Note”). The July 2017 Note is due no later than 90 days after the receipt of a minimum of $1,000,000 of funding. The July 2017 Note bears no interest; however, if it is not paid by the due date, interest will accrue at the rate of 12% per year. During the year ended December 31, 2017, the Company recorded imputed interest expense to a related party in the amount of $4,500 on the July 2017 Note.

Note 6 - Stockholders' Deficit

Note 6 - Stockholders' Deficit	12 Months Ended
	Dec. 31, 2017
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	Note 6 – Stockholders’ Deficit Sale of Common Stock During the year ended December 31, 2017, the Company raised gross proceeds of $47,000 through the sale of 250,000 shares of common stock to a new member of the Board of Directors and a third party investor at an average price of $0.188 per share. Shares for Stock Based Compensation During the year ended December 31, 2017, the Company issued 2,113,637 restricted shares of the Company’s common stock valued at $261,534 in exchange for services conducted on behalf of the Company. The value of these shares was based on the closing market price on the respective date of grant Shares issued for convertible note payable issuance During the year ended December 31, 2017, The Company also issued 65,000 shares of common stock with a fair value of $10,773 for the extension of a note payable. Shares issued for conversion of accounts payable During the year ended December 31, 2017, the Company issued 1,215,571 shares of common stock for the conversion of accounts payable in the amount of $108,986. Shares issued for conversion of debt Debt beneficial conversion feature for convertible note payable Stock payable for debt Stock returned for cancellation

Note 7 - Stock Options

Note 7 - Stock Options	12 Months Ended
	Dec. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	Note 7 – Stock Options The Company had two Employee, Director and Consultant Stock Option Plans that were not terminated as a result of the fiscal 2015 restructuring of the Company and spin-out and have continued as part of the operations as detailed below. In fiscal 2015, the option pool pertaining to the 2009 Employee, Director and Consultant Stock Option Plan (the “2009 Plan”) was adjusted for a 1 for 101 stock split due to the spin-out and restructuring plan, resulting in an authorized option pool of 18,152. Stock options typically vest over a three-year period and have a life of ten years from the date granted. As of December 31, 2017, there were 3,610 shares available for future awards under this plan. In fiscal 2015, the option pool pertaining to the 2012 Employee, Director and Consultant Stock Option Plan (the “2012 Plan”) was adjusted for a 1 for 101 stock split due to the spin-out and restructuring plan, resulting in an authorized options pool of 74,257. Stock options typically vest over a three-year period and have a life of ten years from the date granted. As of December 31, 2017, there were 45,673 shares available for future awards under this plan. In addition, there are approximately 24,753 in options outstanding that were issued to a former CEO of spin-out Company in fiscal 2014. These options issued are outside of the 2009 and 2012 Plans. On June 1, 2016 Jim Driscoll was granted for his position as Chief Executive Officer (CEO) of the Company options to purchase up to 1,000,000 shares of Common Stock outside of the Company’s 2009 and 2012 stock option plans (the “Option Agreement”). These options covered 250,000 shares at an exercise price of $1.00 per share to be granted immediately and three additional tranches of 250,000 shares each at an exercise price of $1.50, $2.00 and $2.50 per share, respectively. The remaining three tranches will vest equally over the next three years with the first fully vesting on May 31, 2017 through May 31, 2019. The term of the options will be for a period of five years and may be exercised at any time as to the vested shares. These options were fully cancelled in conjunction with his resignation as of September 27, 2016. During the fiscal year ended December 31, 2016, the Company recorded stock compensation expense related to the options granted to Mr. Driscoll of $314,680. The grant-date fair value of options was estimated using the Black-Scholes option pricing model. The per share weighted average fair value of stock options granted for Mr. Driscoll was a range of $1.35-$1.76 and was determined using the following assumptions: expected price volatility is 80.39%, risk-free interest rate of 1.39%, zero expected dividend yield, and 4.0 years expected life of options. The expected term of options granted is based on the simplified method in accordance with Securities and Exchange Commission Staff Accounting Bulletin 107, and represents the period of time that options granted are expected to be outstanding. The Company makes assumptions with respect to expected stock price volatility based on the average historical volatility of peers with similar attributes. In addition, the Company determines the risk free rate by selecting the U.S. Treasury with maturities similar to the expected terms of grants, quoted on an investment basis in effect at the time of grant for that business day. As a result of the cancellation of these warrants, the Company has recovered $314,680 as resulted of the elimination of this reserve. As of December 31, 2017, unrecognized stock compensation expense related to unvested stock options under all Plans was $0. Total stock compensation expense recorded to selling, general and administrative expenses on the consolidated statements of operations and comprehensive for the fiscal year ended December 31, 2017 related to the all Plans and options that vested during the period was $0. A summary of options issued, exercised and cancelled are as follows: Shares Weighted- Average Exercise Price ($) Weighted- Average Remaining Contractual Term Aggregate Intrinsic Value ($) Outstanding at December 31, 2016 67,879 $ 21.40 6.17 — Granted — — — — Cancelled — — — — Outstanding at December 31, 2017 67,879 $ 21.40 5.17 — Exercisable at December 31, 2017 67,879 $ 21.40 5.17 —

Note 8 - Stock Warrants

Note 8 - Stock Warrants	12 Months Ended
	Dec. 31, 2017
Disclosure Text Block Supplement [Abstract]
Shareholders' Equity and Share-based Payments [Text Block]	Note 8– Stock Warrants Subsequent to the restructuring of the Company and the spin-out, the Company had warrants to purchase common stock outstanding that were not terminated and have continued as part of the operations as detailed below. The warrants were adjusted for a 1 for 101 stock split due to the spin-out and restructuring plan as authorized. All warrants outstanding as of December 31, 2017 are scheduled to expire at various dates through 2019. A summary of warrants issued, exercised and expired are as follows: Shares Weighted- Average Exercise Price ($) Weighted- Average Remaining Contractual Term Outstanding at December 31, 2016 142,653 $ 17.42 2.25 Granted — — — Expired — — — Outstanding at December 31, 2017 142,653 $ 17.42 1.25 Exercisable at December 31, 2017 142,653 $ 17.42 1.25

Note 9 - Income Taxes

Note 9 - Income Taxes	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	Note 9 – Income Taxes The Company accounts for income taxes under standards issued by the FASB. Under those standards, deferred tax assets and liabilities are recognized for future tax benefits or consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for significant deferred tax assets when it is more likely than not that such assets will not be realized through future operations. No provision for federal income taxes has been recorded due to the available net operating loss carry forwards of approximately $1,803,912 will expire in various years through 2034. Future tax benefits which may arise as a result of these losses have not been recognized in these financial statements, as their realization is determined not likely to occur and accordingly, the Company has recorded a valuation allowance for the future tax loss carry forwards. The actual income tax provisions differ from the expected amounts calculated by applying the statutory income tax rate to the Company’s loss before income taxes. The components of these differences are as follows at December 31, 2017 and December 31, 2016: 2017 2016 Net tax loss carry-forwards $ 1,832,083 $ 1,351,095 Statutory rate 21 % 34 % Expected tax recovery 384,737 459,372 Change in valuation allowance (384,737 ) (459,372 ) Income tax provision $ - $ - Components of deferred tax asset: Non capital tax loss carry forwards $ 384,737 $ 459,372 Less: valuation allowance (384,737 ) (459,372 ) Net deferred tax asset $ - $ -

Note 10 - Commitments and Conti

Note 10 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	Note 10 – Commitments and Contingencies Legal National Council for Science and the Environment, Inc. v. Trunity Holdings, Inc., Case No. 2015 CA 009726 B, Superior Court for the District of Columbia, Civil Division. This action was filed on December 16, 2015 by the National Council for Science and the Environment, Inc. (“NCSE”) in the state court in the District of Columbia against Trunity Holdings, Inc. (“Trunity”) and alleges claims for breach of contract. Acknowledgement of indebtedness and settlement agreement and quantum meruit arising out of an agreement entered into between NCSE and Trunity in 2014. The complaint seeks damages in the amount of $177,270, inclusive of attorney’s fees, costs and accrued interest, continuing interest in the amount of 12% per annum and attorney’s fees and costs of collection relating to the case. The Company, in its answer dated January 27, 2016, denied the material allegations made by NCSE, asserted a number of affirmative defenses and filed a counterclaim alleging claims for fraud, negligent misrepresentation, breach of fiduciary duty, breach of contract and unjust enrichment. In its counterclaim, the Company sought actual and compensatory damages against NCSE that it believes exceed the amount sought by NCSE on its claims, pre-judgment interest, punitive damages and all costs and expenses, including attorney’s fees, incurred by the Company in bringing its claims against NCSE. On September 23, 2016, the Company settled this obligation with an agreement to pay $48,500 to NCSE if paid by November 4, 2016, and $75,000 if paid later. The Company has not paid the amounts as of the date of this filing, and has recorded the obligation at $75,000. Carlton Fields Jorden Burt, P.A. vs. True Nature Holding, Inc., f/k/a/ Trunity Holdings, Inc. This action was filed on May 18, 2017 by a law firm that represented the Company prior to the spin-out of the educational software business in 2016 with the intent of collection past due invoices in the aggregate amount of $241,828. The Company believes it has strong defenses against any such action and anticipates a settlement upon completion of certain funding activities. The Company has recorded a liability in the amount of $241,828 on its balance sheet at December 31, 2017. 230 Commerce Way, LLC vs. Trunity, Inc. A former landlord of the Company has filed an action in New Hampshire to collect on rent from a list that existed prior to 2013. In January 2018 this action was settled by the spin out, Trunity, Inc. for a cash payment of $65,000. Trunity, Inc. The spin-out that now owns the former educational software business has been informed that they owe the Company from the obligations of the NCSE settlement, and the costs of the legal action. We intend to take all actions available to us to collect on these amounts.

Note 11 - Financial Condition a

Note 11 - Financial Condition and Going Concern	12 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Substantial Doubt about Going Concern [Text Block]	Note 11 – Financial Condition and Going Concern As of December 31, 2017, the Company had no cash and current liabilities of $1,387,251 and has incurred a loss from operations. True Nature Holding’s principal operation is the acquisition of compounding pharmacy companies. The Company’s activities are subject to significant risks and uncertainties, including failing to secure additional funding to execute its business plan. As a result of these factors, there is substantial doubt about the ability of the Company to continue as a going concern. The Company’s continuance is dependent on raising capital and generating revenues sufficient to sustain operations. The Company believes that the necessary capital will be raised and has entered into discussions to do so with certain individuals and companies. However, as of the date of these consolidated financial statements, no formal agreement exists. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts classified as liabilities that might be necessary should the Company be forced to take any such actions.

Note 12 - Subsequent Events

Note 12 - Subsequent Events	12 Months Ended
	Dec. 31, 2017
Subsequent Events [Abstract]
Subsequent Events [Text Block]	Note 12 – Subsequent Events On January 29, 2018, the Company issued an aggregate 1,347,431 shares of common stock to four ex-officer or directors for the satisfaction of accrued compensation. Also on January 29, 2018, the Company issued 557,692 to an investor for the payment of accounts payable on behalf of the Company in the amount of $58,000, On March 13, 2018, the Company executed a non-binding letter of intent for the purchase all of the outstanding shareholder interests of Local Pet RX, Inc., (Local Pet RX), based in Jacksonville, Florida, and its affiliates and predecessors. Local Pet RX is a provider of software and services aimed at allowing local pharmacy operators to effective enter the veterinary marketplaces. As of April 1, 2018 the Company Appointed Mr. Jay Morton to the positions of President and Interim Chief Executive Officer (CEO), effective April 1, 2018. Mr. Morton, age 51, founded Local Pet RX in 2014, where he and four other shareholders have developed a “telemedicine” like application for use by pharmacies and veterinary clinics, aimed at processing orders from the veterinary clinics online, while allowing the end user pet owners to interface with both the veterinary clinic and the filling pharmacy business. We evaluated subsequent events after the balance sheet date through the date the financial statements were issued. We did not identify any additional material events or transactions occurring during this subsequent event reporting period that required further recognition or disclosure in these financial statements.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Accounting
Use of Estimates, Policy [Policy Text Block]	Use of Estimates -
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Loss –
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash -
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition –
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation – Equity instruments issued to other than employees are recorded on the basis of the fair value of the instruments. In general, the measurement date is when either a (a) performance commitment, as defined, is reached or (b) the earlier of (i) the non-employee performance is complete or (ii) the instruments are vested. The measured value related to the instruments is recognized over a period based on the facts and circumstances of each particular grant.
Convertible Instruments, Policy [Policy Text Block]	Convertible Instruments
Warrants, Policy [Policy Text Block]	Common Stock Purchase Warrants –
Stockholders' Equity, Policy [Policy Text Block]	Stockholders’ Equity –
Earnings Per Share, Policy [Policy Text Block]	Per Share Data – The Company has excluded all common equivalent shares outstanding for warrants, options and convertible instruments to purchase common stock from the calculation of diluted net loss per share because all such securities are antidilutive for the periods presented. As of December 31, 2017 and 2016, the Company had no outstanding warrants or options.
Income Tax, Policy [Policy Text Block]	Income Taxes – Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company has determined that a valuation allowance is needed due to recent taxable net operating losses, the sale of profitable divisions and the limited taxable income in the carry back periods. The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income or expense in the period that includes the enactment date. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and certain tax loss carryforwards, less any valuation allowance. The Company accounts for uncertain tax positions as required in that a position taken or expected to be taken in a tax return is recognized in the consolidated financial statements when it is more likely than not (i.e., a likelihood of more than fifty percent) that the position would be sustained upon examination by tax authorities. A recognized tax position is then measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. The Company does not have any material unrecognized tax benefits. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as components of interest expense and other expense, respectively, in arriving at pretax income or loss. The Company does not have any interest and penalties accrued. The Company is generally no longer subject to U.S. federal, state, and local income tax examinations for the years before 2012.
Business Combinations Policy [Policy Text Block]	Business Combinations – ● future expected cash flows from product sales, support agreements, consulting contracts, other customer contracts, and acquired developed technologies and patents; and ● discount rates utilized in valuation estimates. Unanticipated events and circumstances may occur that may affect the accuracy or validity of such assumptions, estimates or actual results. Additionally, any change in the fair value of the acquisition-related contingent consideration subsequent to the acquisition date, including changes from events after the acquisition date, such as changes in our estimates of relevant revenue or other targets, will be recognized in earnings in the period of the estimated fair value change. A change in fair value of the acquisition-related contingent consideration or the occurrence of events that cause results to differ from our estimates or assumptions could have a material effect on the consolidated financial position, statements of operations or cash flows in the period of the change in the estimate.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long – Lived Assets-
Fair Value of Financial Instruments, Policy [Policy Text Block]	Financial Instruments and Fair Values – Level 1 – inputs include exchange quoted prices for identical instruments and are the most observable. Level 2 – inputs include brokered and/or quoted prices for similar assets and observable inputs such as interest rates. Level 3 – inputs include data not observable in the market and reflect management judgment about the assumptions market participants would use in pricing the asset or liability. The use of observable and unobservable inputs and their significant in measuring fair value are reflected in our hierarchy assessment. The carrying amount of cash, prepaid assets, accounts payable and accrued liabilities approximates fair value due to the short-term maturities of these instruments. Because cash and cash equivalents are readily liquidated, management classifies these values as Level 1. The fair value of the debentures, approximate their book value as the instruments are short-term in nature and contain market rates of interest. Because there is no ready market or observable transactions, management classifies the debentures as Level 3.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Standards In May 2017, the FASB issued ASU No. 2017-09, Stock Compensation - Scope of Modification Accounting, which provides guidance on which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. The ASU requires that an entity should account for the effects of a modification unless the fair value (or calculated value or intrinsic value, if used), vesting conditions and classification (as equity or liability) of the modified award are all the same as for the original award immediately before the modification. The ASU becomes effective for the Company on January 1, 2018, and should be applied prospectively to an award modified on or after the adoption date. Early adoption is permitted, including adoption in any interim period. The Company will apply this standard for any awards that are modified after January 1, 2018. We are evaluating what impact, if any, the adoption of this guidance will have on our financial condition, results of operations, cash flows or financial disclosures. In January 2017, the FASB issued ASU No. 2017-04, Simplifying the Test for Goodwill Impairment, which simplifies the subsequent measurement of goodwill by eliminating Step 2 from the goodwill impairment test. In computing the implied fair value of goodwill under Step 2, current U.S. GAAP requires the performance of procedures to determine the fair value at the impairment testing date of assets and liabilities (including unrecognized assets and liabilities) following the procedure that would be required in determining the fair value of assets acquired and liabilities assumed in a business combination. Instead, the amendments under this ASU require the goodwill impairment test to be performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. The ASU becomes effective for the Company on January 1, 2020. The amendments in this ASU should be applied on a prospective basis. Early adoption is permitted for interim or annual goodwill impairment tests performed. We are evaluating what impact, if any, the adoption of this guidance will have on our financial condition, results of operations, cash flows or financial disclosures. In August 2016, the FASB issued ASU No. 2016-15 which amends ASC Topic 230, “Classification of Certain Cash Receipts and Cash Payments.” The amendments in this update address eight specific cash flow issues with the objective of reducing the existing diversity in practice. The update outlines the classification of specific transactions as either cash inflows or outflows from financing activities, operating activities, investing activities or non-cash activities. This guidance is effective for interim and annual reporting periods beginning after December 15, 2017. We are evaluating what impact, if any, the adoption of this guidance will have on our financial condition, results of operations, cash flows or financial disclosures. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), to increase transparency and comparability among organizations by recognizing a right-of-use asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either operating or financing, with such classification affecting the pattern of expense recognition in the income statement. ASU 2016-02 is effective for fiscal years and interim periods within those years beginning after December 15, 2018, and early adoption is permitted. We are currently evaluating the impact ASU 2016-02 will have on our consolidated financial statements and associated disclosures. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), to clarify the principles of recognizing revenue and create common revenue recognition guidance between U.S. GAAP and International Financial Reporting Standards. Under ASU 2014-09, revenue is recognized when a customer obtains control of promised goods or services and is recognized at an amount that reflects the consideration expected to be received in exchange for such goods or services. In addition, ASU 2014-09 requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The ASU is effective for fiscal years beginning after December 15, 2017. The new revenue standard is principle based and interpretation of those principles may vary from company to company based on their unique circumstances. It is possible that interpretation, industry practice, and guidance may evolve as companies and the accounting profession work to implement this new standard. The Company is still in the process of evaluating the effect of the new standard on the Company’s historical financial statements and disclosures. While the Company has not completed its evaluation, the Company currently believes that the impact to revenue and expense recognized will not be material to any of the years presented. Management does not believe that any other recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on the accompanying condensed consolidated financial statements.

Note 7 - Stock Options (Tables)

Note 7 - Stock Options (Tables)	12 Months Ended
	Dec. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of options issued, exercised and cancelled are as follows: Shares Weighted- Average Exercise Price ($) Weighted- Average Remaining Contractual Term Aggregate Intrinsic Value ($) Outstanding at December 31, 2016 67,879 $ 21.40 6.17 — Granted — — — — Cancelled — — — — Outstanding at December 31, 2017 67,879 $ 21.40 5.17 — Exercisable at December 31, 2017 67,879 $ 21.40 5.17 —

Note 8 - Stock Warrants (Tables

Note 8 - Stock Warrants (Tables)	12 Months Ended
	Dec. 31, 2017
Disclosure Text Block Supplement [Abstract]
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	A summary of warrants issued, exercised and expired are as follows: Shares Weighted- Average Exercise Price ($) Weighted- Average Remaining Contractual Term Outstanding at December 31, 2016 142,653 $ 17.42 2.25 Granted — — — Expired — — — Outstanding at December 31, 2017 142,653 $ 17.42 1.25 Exercisable at December 31, 2017 142,653 $ 17.42 1.25

Note 9 - Income Taxes (Tables)

Note 9 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	The actual income tax provisions differ from the expected amounts calculated by applying the statutory income tax rate to the Company’s loss before income taxes. The components of these differences are as follows at December 31, 2017 and December 31, 2016: 2017 2016 Net tax loss carry-forwards $ 1,832,083 $ 1,351,095 Statutory rate 21 % 34 % Expected tax recovery 384,737 459,372 Change in valuation allowance (384,737 ) (459,372 ) Income tax provision $ - $ - Components of deferred tax asset: Non capital tax loss carry forwards $ 384,737 $ 459,372 Less: valuation allowance (384,737 ) (459,372 ) Net deferred tax asset $ - $ -

Note 1 - Organization, Basis 23

Note 1 - Organization, Basis of Presentation and Nature of Operations (Details) - $ / shares	Jan. 16, 2016	Dec. 31, 2017	Dec. 31, 2016
Disclosure Text Block [Abstract]
Stockholders' Equity, Reverse Stock Split	1 for 101
Capital Stock, Share Authorized		510,000,000
Common Stock, Shares Authorized		500,000,000	500,000,000
Common Stock, Par or Stated Value Per Share (in Dollars per share)		$ 0.01	$ 0.01
Preferred Stock, Shares Authorized		10,000,000	10,000,000
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)		$ 0.01	$ 0.01

Note 2 - Summary of Significa24

Note 2 - Summary of Significant Accounting Policies (Details)	Jan. 16, 2016
Accounting Policies [Abstract]
Stockholders' Equity, Reverse Stock Split	1 for 101

Note 3 - Deconsolidation of a25

Note 3 - Deconsolidation of acquisition (Details) - USD ($)	Apr. 29, 2016	Apr. 25, 2016	Jan. 25, 2016	Jun. 30, 2016	Dec. 31, 2017	Dec. 31, 2016
Note 3 - Deconsolidation of acquisition (Details) [Line Items]
Fair Value of Shares Issued, Deconsolidation						$ 1,618,200
Conversion of Stock, Amount Issued						$ 1,183,200
Stock Issued During Period, Shares, Issued for Services (in Shares)		100,000	100,000			4,070,000
Sale of Stock, Price Per Share (in Dollars per share)					$ 0.188	$ 0.50
Stock Issued During Period, Value, Issued for Services			$ 145,000		$ 261,534	$ 3,377,735
Deconsolidation, Gain (Loss), Amount						$ (1,618,200)
Restricted Stock 1 [Member] | P3 Convertible Note [Member]
Note 3 - Deconsolidation of acquisition (Details) [Line Items]
Conversion of Stock, Shares Issued (in Shares)						340,000
VP of Corporate Development [Member] | Restricted Stock 1 [Member]
Note 3 - Deconsolidation of acquisition (Details) [Line Items]
Employment Contract, Term				3 years
Annual Salary Owed to Related Party				$ 125,000
Stock Issued During Period, Shares, Issued for Services (in Shares)	125,000
Sale of Stock, Price Per Share (in Dollars per share)	$ 3.48
Stock Issued During Period, Value, Issued for Services				$ 435,000

Note 4 - Related Party Transa26

Note 4 - Related Party Transactions (Details)	Dec. 30, 2016USD ($)shares	Sep. 30, 2016USD ($)shares	Sep. 27, 2016USD ($)shares	Sep. 23, 2016USD ($)shares	May 25, 2016USD ($)shares	Apr. 25, 2016shares	Jan. 25, 2016USD ($)shares	Dec. 31, 2017USD ($)$ / sharesshares	Dec. 31, 2016USD ($)$ / sharesshares	Dec. 30, 2016USD ($)
Note 4 - Related Party Transactions (Details) [Line Items]
Number of Board Members							2			2
Stock Issued During Period, Shares, Issued for Services (in Shares) | shares						100,000	100,000		4,070,000
Stock Issued During Period, Value, Issued for Services							$ 145,000	$ 261,534	$ 3,377,735
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares) | shares			1,000,000			1,000,000		0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period (in Shares) | shares				1,000,000
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in Shares) | shares			100,000	100,000
Stock Issued During Period, Value, Restricted Stock Award, Gross	$ 57,240			$ 47,680
Number of Directors	3
Agreement, Monthly Amount		$ 10,000
Restricted Stock Award, Forfeitures			$ 2,000,000
Stock Issued During Period, Shares, Other (in Shares) | shares		966,666						65,000
Stock Issued During Period, Value, Other		$ 290,000						$ 10,773	138,751
Increase (Decrease) in Due to Related Parties		(290,000)						59,200	106,866
Due to Related Parties, Current	$ 75,866							91,066	106,866	$ 75,866
Stock Issued During Period, Shares, Share-based Compensation, Gross (in Shares) | shares	100,000
Stock Issued During Period, Value, Share-based Compensation, Gross	$ 19,080
Accounts Payable, Related Parties, Current	106,866									106,866
Accrued Salaries, Current	12,000									12,000
Due to Officers or Stockholders, Current	$ 7,000									$ 7,000
Proceeds from Issuance or Sale of Equity								$ 47,000	$ 51,000
Stock Issued During Period, Shares, New Issues (in Shares) | shares								50,000	120,000
Sale of Stock, Price Per Share (in Dollars per share) | $ / shares								$ 0.188	$ 0.50
Accrued Salaries								$ 147,894
Due from Related Parties								91,066
Notes Payable, Related Parties								75,000
Interest Expense, Related Party								4,500
Issued to Each Director [Member]
Note 4 - Related Party Transactions (Details) [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in Shares) | shares	100,000
Stock Issued During Period, Value, Restricted Stock Award, Gross	$ 19,080
Director [Member]
Note 4 - Related Party Transactions (Details) [Line Items]
Stock Issued During Period, Shares, Issued for Services (in Shares) | shares					100,000
Stock Issued During Period, Value, Issued for Services					$ 235,000
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in Shares) | shares				100,000
Stock Issued During Period, Value, Restricted Stock Award, Gross				$ 27,990
Number of Directors				3
Proceeds from Issuance or Sale of Equity								$ 47,000
Stock Issued During Period, Shares, New Issues (in Shares) | shares								250,000
Sale of Stock, Price Per Share (in Dollars per share) | $ / shares								$ 0.157
Former Chief Executive Officer [Member]
Note 4 - Related Party Transactions (Details) [Line Items]
Agreement, Monthly Amount			10,000
Related Party [Member]
Note 4 - Related Party Transactions (Details) [Line Items]
Stock Issued During Period, Shares, Issued for Services (in Shares) | shares								1,533,571
Stock Issued During Period, Value, Issued for Services								$ 179,024
Employment Agreement, Monthly Salary 2016 [Member] | Former Chief Executive Officer [Member]
Note 4 - Related Party Transactions (Details) [Line Items]
Agreement, Monthly Amount			12,500
Employment Agreement, Monthly Salary 2017 [Member] | Former Chief Executive Officer [Member]
Note 4 - Related Party Transactions (Details) [Line Items]
Agreement, Monthly Amount			17,500
Employment Agreement, Monthly Salary 2018 [Member] | Former Chief Executive Officer [Member]
Note 4 - Related Party Transactions (Details) [Line Items]
Agreement, Monthly Amount			22,500
Employment Agreement, Monthly Salary 2019 [Member] | Former Chief Executive Officer [Member]
Note 4 - Related Party Transactions (Details) [Line Items]
Agreement, Monthly Amount			$ 25,000
Advances to the Company [Member]
Note 4 - Related Party Transactions (Details) [Line Items]
Due to Related Parties, Current		80,000
Consulting Fees [Member]
Note 4 - Related Party Transactions (Details) [Line Items]
Due to Related Parties, Current		120,000
Costs Related to Acquisition [Member]
Note 4 - Related Party Transactions (Details) [Line Items]
Due to Related Parties, Current		$ 90,000

Note 5 - Debt (Details)

Note 5 - Debt (Details) - USD ($)	Aug. 10, 2017	Jul. 10, 2017	Dec. 30, 2016	Sep. 30, 2016	Sep. 19, 2016	May 19, 2016	Mar. 18, 2016	Nov. 30, 2014	Aug. 31, 2014	Dec. 31, 2017	Dec. 31, 2016
Note 5 - Debt (Details) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		12.00%
Debt Instrument, Face Amount		$ 75,000
Stock Issued During Period, Shares, Other (in Shares)				966,666						65,000
Stock Issued During Period, Shares, Conversion of Convertible Securities (in Shares)	25,000
Stock Issued During Period, Value, Conversion of Convertible Securities	$ 3,750									$ 108,986	$ 580,000
Interest Payable, Current										50,665	31,021
Debt Instrument, Convertible, Beneficial Conversion Feature										0	67,062
Amortization of Debt Discount (Premium)										$ 0	249,592
Class of Warrant or Rights, Granted (in Shares)										0
Stock Issued During Period, Value, Other				$ 290,000						$ 10,773	138,751
Debt Conversion, Original Debt, Amount				100,000						0	103,671
Gain (Loss) on Extinguishment of Debt				$ (16,329)						0	(206,329)
Debt Instrument, Maturity Date, Description		The July 2017 Note is due no later than 90 days after the receipt of a minimum of $1,000,000 of funding.
Interest Expense, Related Party										$ 4,500
Convertible Note A [Member]
Note 5 - Debt (Details) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage							12.00%
Debt Instrument, Face Amount							$ 60,000
Stock Issued During Period, Shares, Other (in Shares)					15,000		15,000			65,000
Shares Issued, Price Per Share (in Dollars per share)					$ 0.30
Debt Instrument, Fee Amount					$ 4,050
Interest Payable, Current										$ 10,860	3,660
Debt Instrument, Periodic Payment							$ 1,000
Debt Instrument, Convertible, Conversion Price (in Dollars per share)							$ 1
Debt Instrument, Unamortized Discount							$ 18,750				16,364
Debt Instrument, Convertible, Beneficial Conversion Feature							$ 9,375
Amortization of Debt Discount (Premium)											28,125
Interest Expense, Debt										7,200	296
Stock Issued During Period, Value, Other										10,773
Convertible Note B [Member]
Note 5 - Debt (Details) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage						10.00%
Debt Instrument, Face Amount						$ 100,000
Stock Issued During Period, Shares, Other (in Shares)				400,000
Debt Instrument, Unamortized Discount						$ 100,000
Warrant Term						24 months
Class of Warrant or Rights, Granted (in Shares)						66,666
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)						$ 2.50
Warrants, Fair Value of Warrants, Granted						$ 103,086
Interest Expense, Debt						$ 3,086
Stock Issued During Period, Value, Other				$ 120,000
Gain (Loss) on Extinguishment of Debt											16,329
Series C Debenture [Member]
Note 5 - Debt (Details) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage									10.00%
Debt Instrument, Face Amount									$ 100,000
Debt Instrument, Convertible, Conversion Price (in Dollars per share)									$ 20.20
Warrant Term									5 years
Class of Warrant or Rights, Granted (in Shares)									4,950
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)									$ 20.20
Interest Expense, Debt										35,504	24,420
Convertible Debt									$ 110,833	110,833
Series D Debenture [Member]
Note 5 - Debt (Details) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage								12.00%
Debt Instrument, Face Amount								$ 10,000
Debt Instrument, Convertible, Conversion Price (in Dollars per share)								$ 16.67
Warrant Term								5 years
Class of Warrant or Rights, Granted (in Shares)								495
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)								$ 20.20
Interest Expense, Debt										4,301	2,941
Convertible Debt								$ 11,333		11,333
Notes Payable, Other Payables [Member]
Note 5 - Debt (Details) [Line Items]
Repayments of Short-term Debt										67,676	0
P3 Compounding of Georgia, LLC [Member]
Note 5 - Debt (Details) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			10.50%
Debt Instrument, Face Amount											52,000
Debt Instrument, Fee Amount			$ 2,000								22,280
Debt Instrument, Periodic Payment			451.75
Proceeds from Short-term Debt			$ 50,000
Debt Instrument, Term			160 days
Debt Instrument, Frequency of Periodic Payment			repayment amount of $451.75 per day
Short-term Debt			$ 72,280
Notes Payable										$ 74,104	26,925
Principal [Member]
Note 5 - Debt (Details) [Line Items]
Debt Conversion, Original Debt, Amount				$ 3,671
Principal [Member] | Convertible Note B [Member]
Note 5 - Debt (Details) [Line Items]
Debt Conversion, Original Debt, Amount											100,000
Interest Expense [Member] | Convertible Note B [Member]
Note 5 - Debt (Details) [Line Items]
Debt Conversion, Original Debt, Amount											$ 3,671

Note 6 - Stockholders' Deficit

Note 6 - Stockholders' Deficit (Details)	Aug. 10, 2017shares	Sep. 30, 2016USD ($)shares	May 25, 2016USD ($)shares	Apr. 25, 2016shares	Jan. 25, 2016USD ($)shares	Dec. 31, 2017USD ($)$ / sharesshares	Dec. 31, 2016USD ($)$ / sharesshares
Note 6 - Stockholders' Deficit (Details) [Line Items]
Proceeds from Issuance of Common Stock							$ 60,000
Stock Issued During Period, Shares, New Issues (in Shares) | shares						50,000	120,000
Sale of Stock, Price Per Share (in Dollars per share) | $ / shares						$ 0.188	$ 0.50
Payments of Stock Issuance Costs						$ 9,000
Stock Issued During Period, Shares, Issued for Services (in Shares) | shares				100,000	100,000		4,070,000
Stock Issued During Period, Value, Issued for Services					$ 145,000	$ 261,534	$ 3,377,735
Debt Conversion, Converted Instrument, Shares Issued (in Shares) | shares		400,000				1,215,571
Debt Conversion, Original Debt, Amount		$ 100,000				$ 0	103,671
Stock Issued During Period, Shares, Other (in Shares) | shares		966,666				65,000
Stock Issued During Period, Value, Other		$ 290,000				$ 10,773	138,751
Gain (Loss) on Extinguishment of Debt		(16,329)				0	(206,329)
Debt Conversion, Converted Instrument, Amount						108,986
Proceeds from Convertible Debt						0	258,000
Debt Instrument, Convertible, Beneficial Conversion Feature						$ 0	$ 67,062
Number of Notes						2
Common Stock, Value, Subscriptions						$ 10,000
Stock Repurchased and Retired During Period, Shares (in Shares) | shares	2,150,000
Director [Member]
Note 6 - Stockholders' Deficit (Details) [Line Items]
Proceeds from Issuance of Common Stock						$ 47,000
Stock Issued During Period, Shares, New Issues (in Shares) | shares						250,000
Sale of Stock, Price Per Share (in Dollars per share) | $ / shares						$ 0.157
Stock Issued During Period, Shares, Issued for Services (in Shares) | shares			100,000
Stock Issued During Period, Value, Issued for Services			$ 235,000
Accounts Payable [Member]
Note 6 - Stockholders' Deficit (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued (in Shares) | shares							1,066,666
Debt Conversion, Original Debt, Amount							$ 580,000
Gain (Loss) on Extinguishment of Debt							$ (190,000)
Principal [Member]
Note 6 - Stockholders' Deficit (Details) [Line Items]
Debt Conversion, Original Debt, Amount		$ 3,671
Shares Issued for Services [Member]
Note 6 - Stockholders' Deficit (Details) [Line Items]
Stock Issued During Period, Shares, Issued for Services (in Shares) | shares						2,113,637
Stock Issued During Period, Value, Issued for Services						$ 261,534
Convertible Debt [Member]
Note 6 - Stockholders' Deficit (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued (in Shares) | shares							15,000
Debt Conversion, Original Debt, Amount							$ 18,750
Proceeds from Convertible Debt							201,780
Debt Instrument, Convertible, Beneficial Conversion Feature							$ 67,062

Note 7 - Stock Options (Details

Note 7 - Stock Options (Details)	Sep. 27, 2016shares	Jun. 01, 2016$ / sharesshares	Apr. 25, 2016shares	Jan. 16, 2016	Dec. 31, 2017USD ($)$ / sharesshares	Dec. 31, 2016USD ($)$ / shares	Dec. 30, 2016shares
Note 7 - Stock Options (Details) [Line Items]
Number of Plans					2
Stockholders' Equity, Reverse Stock Split				1 for 101
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number					67,879		67,879
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	1,000,000		1,000,000		0
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share) | $ / shares					$ 0
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options (in Dollars) | $					$ 0
Share-based Compensation (in Dollars) | $					$ 261,534	$ 3,377,736
2009 Employee, Director and Consultant Stock Option Plan ("2009 Plan") [Member]
Note 7 - Stock Options (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized					18,152
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period					10 years
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant					3,610
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period					3 years
2012 Employee, Director and Consultant Stock Option Plan ("2012 Plan") [Member]
Note 7 - Stock Options (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized					74,257
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period					10 years
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant					45,673
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period					3 years
Selling, General and Administrative Expenses [Member]
Note 7 - Stock Options (Details) [Line Items]
Share-based Compensation (in Dollars) | $					$ 0
Former Chief Executive Officer [Member]
Note 7 - Stock Options (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number					24,753
Chief Executive Officer [Member]
Note 7 - Stock Options (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period		5 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		1,000,000
Allocated Share-based Compensation Expense (in Dollars) | $						$ 314,680
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum						80.39%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum						1.39%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate						0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term						4 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Recovered in Period, Gross (in Dollars) | $						$ 314,680
Chief Executive Officer [Member] | Option at $1 [Member]
Note 7 - Stock Options (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		250,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share) | $ / shares		$ 1
Chief Executive Officer [Member] | Option at $1.5 [Member]
Note 7 - Stock Options (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		250,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share) | $ / shares		$ 1.50
Chief Executive Officer [Member] | Option at $2 [Member]
Note 7 - Stock Options (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		250,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share) | $ / shares		$ 2
Chief Executive Officer [Member] | Option at $2.5 [Member]
Note 7 - Stock Options (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		250,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share) | $ / shares		$ 2.50
Chief Executive Officer [Member] | Maximum [Member]
Note 7 - Stock Options (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share) | $ / shares						$ 1.76
Chief Executive Officer [Member] | Minimum [Member]
Note 7 - Stock Options (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share) | $ / shares						$ 1.35
Chief Executive Officer [Member] | Share-based Compensation Award, Tranche Two [Member] | Option at $1.5 [Member]
Note 7 - Stock Options (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		3 years
Chief Executive Officer [Member] | Share-based Compensation Award, Tranche Three [Member] | Option at $2 [Member]
Note 7 - Stock Options (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		3 years
Chief Executive Officer [Member] | Share-based Compensation Award, Tranche Four [Member] | Option at $2.5 [Member]
Note 7 - Stock Options (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		3 years
Chief Executive Officer [Member] | Share-based Compensation Award, Tranche One [Member] | Maximum [Member] | Option at $1 [Member]
Note 7 - Stock Options (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights		May 31, 2017 through May 31, 2019

Note 7 - Stock Options (Detai30

Note 7 - Stock Options (Details) - Share-based Compensation, Stock Options, Activity - USD ($)	Dec. 31, 2016	Sep. 27, 2016	Apr. 25, 2016	Dec. 31, 2017
Share-based Compensation, Stock Options, Activity [Abstract]
Options Outstanding, Shares	67,879
Options Outstanding, Weighted- Average Exercise Price	$ 21.40
Options Outstanding, Weighted- Average Remaining Contractual Term	6 years 62 days			5 years 62 days
Options Outstanding, Aggregate Intrinsic Value	$ 0			$ 0
Options Exercisable, Shares				67,879
Options Exercisable, Weighted- Average Exercise Price				$ 21.40
Options Exercisable, Weighted- Average Remaining Contractual Term				5 years 62 days
Options Exercisable, Aggregate Intrinsic Value				$ 0
Options Granted, Shares		1,000,000	1,000,000	0
Options Granted, Weighted- Average Exercise Price				$ 0
Options Cancelled, Shares				0
Options Cancelled, Weighted- Average Exercise Price				$ 0
Options Outstanding, Shares				67,879
Options Outstanding, Weighted- Average Exercise Price				$ 21.40

Note 8 - Stock Warrants (Detail

Note 8 - Stock Warrants (Details)	Jan. 16, 2016
Disclosure Text Block Supplement [Abstract]
Stockholders' Equity, Reverse Stock Split	1 for 101

Note 8 - Stock Warrants (Deta32

Note 8 - Stock Warrants (Details) - Schedule of Stockholders' Equity Note, Warrants or Rights - $ / shares	Dec. 31, 2016	Dec. 31, 2017
Schedule of Stockholders' Equity Note, Warrants or Rights [Abstract]
Warrants, Outstanding	142,653
Warrants, Outstanding Weighted-Average Exercise Price	$ 17.42	$ 17.42
Warrants, Outstanding Weighted-Average Remaining Contractual Terms	2 years 3 months	1 year 3 months
Warrants, Exercisable		142,653
Warrants, Exercisable Weighted-Average Exercise Price		$ 17.42
Warrants, Exercisable Weighted-Average Remaining Contractual Terms		1 year 3 months
Warrants, Granted		0
Warrants, Granted Weighted-Average Exercise Price		$ 0
Warrants, Expired		0
Warrants, Expired Weighted-Average Exercise Price		$ 0
Warrants, Outstanding		142,653

Note 9 - Income Taxes (Details)

Note 9 - Income Taxes (Details)	Dec. 31, 2017USD ($)
Income Tax Disclosure [Abstract]
Operating Loss Carryforwards	$ 1,803,912

Note 9 - Income Taxes (Detail34

Note 9 - Income Taxes (Details) - Schedule of Effective Income Tax Rate Reconciliation - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Schedule of Effective Income Tax Rate Reconciliation [Abstract]
Net tax loss carry-forwards	$ 1,832,083	$ 1,351,095
Statutory rate	21.00%	34.00%
Expected tax recovery	$ 384,737	$ 459,372
Change in valuation allowance	(384,737)	(459,372)
Income tax provision	0	0
Non capital tax loss carry forwards	384,737	459,372
Less: valuation allowance	(384,737)	(459,372)
Net deferred tax asset	$ 0	$ 0

Note 10 - Commitments and Con35

Note 10 - Commitments and Contingencies (Details) - USD ($)	May 18, 2017	Nov. 04, 2016	Sep. 23, 2016	Dec. 16, 2015	Jan. 31, 2018	Dec. 31, 2017
Note 10 - Commitments and Contingencies (Details) [Line Items]
Loss Contingency, Damages Sought				The complaint seeks damages in the amount of $177,270, inclusive of attorney’s fees, costs and accrued interest, continuing interest in the amount of 12% per annum and attorney’s fees and costs of collection relating to the case.
Loss Contingency, Damages Sought, Value	$ 241,828			$ 177,270
Loss Contingency, Damages Awarded, Value		$ 75,000	$ 48,500
Settlement Liabilities, Current						$ 75,000
Estimated Litigation Liability, Current						$ 241,828
Subsequent Event [Member]
Note 10 - Commitments and Contingencies (Details) [Line Items]
Litigation Settlement, Expense					$ 65,000

Note 11 - Financial Condition36

Note 11 - Financial Condition and Going Concern (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liabilities, Current	$ 1,387,251	$ 1,067,874

Note 12 - Subsequent Events (De

Note 12 - Subsequent Events (Details) - USD ($)	Jan. 29, 2018	Dec. 30, 2016	Sep. 30, 2016	Dec. 31, 2017
Note 12 - Subsequent Events (Details) [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross		100,000
Debt Conversion, Converted Instrument, Shares Issued			400,000	1,215,571
Debt Conversion, Converted Instrument, Amount (in Dollars)				$ 108,986
Subsequent Event [Member]
Note 12 - Subsequent Events (Details) [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross	1,347,431
Debt Conversion, Converted Instrument, Shares Issued	557,692
Debt Conversion, Converted Instrument, Amount (in Dollars)	$ 58,000